Biden Aims for 100 Million COVID Vaccinations in First 100 Days
It will not be an easy task
It will not be an easy task
After Pfizer and Moderna, a slew of other candidates could fill gaps in efficacy, production, or distribution
Lessons from other viruses show that even if vaccines don’t completely stop disease spread, they can still successfully contain it
With a vaccine in limited availability, many still need medicines to keep the virus at bay
Scientists are debating whether to delay, skip or halve doses. But untested tweaks could shake public confidence
In the U.S., a third of Americans are at risk of chronic kidney disease, and age is a major factor. More than half of Americans older than 75 are thought to have some sort of kidney damage...
The job of the oncologist of the future will be to prevent and treat the emergence of disease
Social science offers valuable lessons about ways to convince those who are hesitant about the shots
Companies are scrambling to obtain supplies for hundreds of millions of doses of a type of vaccine that has never been made at this scale before
There is evidence the new variant could be more transmissible, yet vaccines work very well against it
Two RNA vaccines will be useful as U.S. infections surge, but the speedy authorizations complicate clinical trials
Kidney disease affects millions of Americans, but corporate capture of dialysis, along with disparities in treatment and transplant access, mean that not everyone’s journey is the same...
Treatments that reduce suffering and incorporate patient values aren’t common in kidney disease care. That’s changing
Demand for healthy kidneys has long outstripped supply. But better testing and treatment are expanding the donor pool
Minority patients are diagnosed later, stay on dialysis longer and are added to transplant lists less quickly. Why?
Nurse Kristen Choi says health care providers need to better educate patients about possible side effects from the COVID-19 vaccine. Christopher Intagliata reports.
Joint ventures between nephrologists and dialysis centers have expanded treatment. Critics ask: At what cost?
Kidney disease affects millions of Americans, but corporate capture of dialysis, along with disparities in treatment and transplant access, mean that not everyone's journey is the same...
A new California law aims to curb what sponsors say is profiteering by dialysis centers. But are there any easy answers?
Even with vaccines on the way, treatments are needed to prevent the disease from getting worse—and to be ready for COVID-25, COVID-37, and so on
You have free articles left.
Support our award-winning coverage of advances in science & technology.
Already a subscriber? Sign in.